TP53 and non-small cell lung carcinoma: If there is a damaged DNA, p53 will stagnate the cell cycle in the G1 phase and determine the “fate” of the cell based on the results of DNA damage and repair.[7] Gene mutations are found in more than 50% of all malignant tumors, and p53 gene mutation or abnormal expression of p53 protein can be detected in 75% of NSCLC.[8] Increased expression of p53 protein can enhance the sensitivity of non-small cell lung cancer to paclitaxel and cisplatin in vitro.[9] P53 mutation can be used as a predictive marker of adjuvant chemotherapy sensitivity in NSCLC.[10]